Pfizer Favorable Safety Results of Eliquis V. Vitamin K Antagonists in AFib

The Bristol-Myers Squibb–Pfizer Alliance today announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis^® (apixaban) versus vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF) and recent acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention (PCI). Results show that in patients receiving a P2Y12 inhibitor with or without aspirin (antiplatelet therapies), the proportion of patients with major or clinically relevant non-major (CRNM) bleeding at six months was significantly lower for those treated with Eliquis compared to those treated with a VKA (10.5% vs. 14.7%, respectively; hazard ratio [HR]: 0.69, 95% confidence interval [CI]: 0.58-0.81; p-superiority<0.001). These data are featured as a late-breaking oral presentation at the American College of Cardiology’s (ACC) 68th Annual Scientific Session 2019 in New Orleans, LA (Abstract 405-08) and simultaneously published in the New England Journal of Medicine.

https://www.marketscreener.com/PFIZER-23365019/news/Pfizer-AUGUSTUS-Demonstrates-Favorable-Safety-Results-of-Eliquis-Versus-Vitamin-K-Antagonists-in-28181717/